204 related articles for article (PubMed ID: 23379430)
21. IgG1 is the dominant subclass of antibody against glutamic acid decarboxylase among type 1 diabetes in Japanese.
Kasuga A; Shimada A; Ozawa Y; Maruyama T; Oya K; Saruta T
Endocr J; 2000 Feb; 47(1):57-62. PubMed ID: 10811294
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity in the occurrence of a subset of autoantibodies to glutamic acid decarboxylase in autoimmune polyendocrine patients with islet cell antibodies.
Davenport C; Radford PM; Al-Bukhari TA; Lai M; Bottazzo GF; Todd I
Clin Exp Immunol; 1998 Mar; 111(3):497-505. PubMed ID: 9528889
[TBL] [Abstract][Full Text] [Related]
23. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes.
Björk E; Velloso LA; Kämpe O; Karlsson FA
Diabetes; 1994 Jan; 43(1):161-5. PubMed ID: 7505244
[TBL] [Abstract][Full Text] [Related]
24. Immune responses to glutamic acid decarboxylase and insulin in patients with gestational diabetes.
Füchtenbusch M; Bonifacio E; Lampasona V; Knopff A; Ziegler AG
Clin Exp Immunol; 2004 Feb; 135(2):318-21. PubMed ID: 14738462
[TBL] [Abstract][Full Text] [Related]
25. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Tavira B; Cheramy M; Axelsson S; Åkerman L; Ludvigsson J; Casas R
Diabetologia; 2017 Jul; 60(7):1276-1283. PubMed ID: 28357504
[TBL] [Abstract][Full Text] [Related]
26. The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.
Sosenko JM; Yu L; Skyler JS; Krischer JP; Gottlieb PA; Boulware D; Miao D; Palmer JP; Steck AK
Diabetes Technol Ther; 2017 Mar; 19(3):183-187. PubMed ID: 28177779
[TBL] [Abstract][Full Text] [Related]
27. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
28. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes.
Ziegler B; Strebelow M; Rjasanowski I; Schlosser M; Ziegler M
Autoimmunity; 1998; 28(2):61-8. PubMed ID: 9771977
[TBL] [Abstract][Full Text] [Related]
29. Elevated Serum GAD65 and GAD65-GADA Immune Complexes in Stiff Person Syndrome.
Gu Urban GJ; Friedman M; Ren P; Törn C; Fex M; Hampe CS; Lernmark Å; Landegren U; Kamali-Moghaddam M
Sci Rep; 2015 Jun; 5():11196. PubMed ID: 26080009
[TBL] [Abstract][Full Text] [Related]
30. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
[TBL] [Abstract][Full Text] [Related]
31. GAD antibodies in T1D and LADA--relations to age, BMI, c-peptide, IA-2 and HLA-DRB1*03 and DRB1*04 alleles.
Weber P; Ambrosova P; Canov P; Weberova D; Kuklinek P; Meluzinova H; Matejovska-Kubesova H; Cejkova P; Bielakova K; Cerna M
Adv Gerontol; 2011; 24(2):312-8. PubMed ID: 21957594
[TBL] [Abstract][Full Text] [Related]
32. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.
Ziegler B; Schlosser M; Lühder F; Strebelow M; Augstein P; Northemann W; Powers AC; Ziegler M
Acta Diabetol; 1996 Sep; 33(3):225-31. PubMed ID: 8904930
[TBL] [Abstract][Full Text] [Related]
33. The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset.
Hillman M; Törn C; Landin-Olsson M;
Clin Exp Immunol; 2009 Aug; 157(2):255-60. PubMed ID: 19604265
[TBL] [Abstract][Full Text] [Related]
34. Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Morgenthaler NG; Seissler J; Achenbach P; Glawe D; Payton M; Meinck HM; Christie MR; Scherbaum WA
Autoimmunity; 1997; 25(4):203-11. PubMed ID: 9344328
[TBL] [Abstract][Full Text] [Related]
35. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies.
Dalakas MC; Li M; Fujii M; Jacobowitz DM
Neurology; 2001 Sep; 57(5):780-4. PubMed ID: 11552003
[TBL] [Abstract][Full Text] [Related]
36. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2022 Mar; 38(3):e3500. PubMed ID: 34611978
[TBL] [Abstract][Full Text] [Related]
37. Apraxia in anti-glutamic acid decarboxylase-associated stiff person syndrome: link to corticobasal degeneration?
Bowen LN; Subramony SH; Heilman KM
Ann Neurol; 2015 Jan; 77(1):173-6. PubMed ID: 25100431
[TBL] [Abstract][Full Text] [Related]
38. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
[TBL] [Abstract][Full Text] [Related]
39. Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus.
Lohmann T; Hawa M; Leslie RD; Lane R; Picard J; Londei M
Lancet; 2000 Jul; 356(9223):31-5. PubMed ID: 10892762
[TBL] [Abstract][Full Text] [Related]
40. Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients.
Rodacki M; Zajdenverg L; Albernaz MS; Bencke-Gonçalves MR; Milech A; Oliveira JE
Braz J Med Biol Res; 2004 Nov; 37(11):1645-50. PubMed ID: 15517079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
